Gain detailed insights into the trading activity of Congress members for Oramed Pharmaceuticals on our government trades page. Stay updated on how elected officials are investing in ORMP.

Oramed Pharmaceuticals - Government Trades

Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.

News

Penny Stocks

Short Ideas

Small Cap

Pre-Market Outlook

Markets

Trading Ideas

CALC

FGEN

ORMP

PEPG

As of Feb. 2, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 4 Health Care Stocks That May Crash This Quarter

Intraday Update

Movers

APLD

APOG

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

BBLN

BDRX

BFRI

CFMS

CRCT

FOXO

GSRM

HAIN

KITT

LCUT

LFLY

MEDS

NVVE

ONCS

PIRS

SKLZ

SONN

SPCE

SRGA

SRPT

SWBI

TMPO

TRUP

WORX

XAIR

Gainers


	Kidpik Corp. (NASDAQ: PIK) shares jumped 122% to $1.29. Kidpik teamed up with Disney to celebrate the release of Disney+ original movie &#39;World&#39;s Best&#39;.


Why CarMax Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Earnings

Eurozone

Commodities

Global

GRNQ

U.S. stocks traded lower this morning, with the Dow Jones dropping around 250 points on Friday.

Following the market opening Friday, the Dow traded down 0.74% to 33,695.28 while the NASDAQ fell 0.98% to 13,497.22. The S&amp;P 500, also fell, dropping, 0.78% to 4,347.58.

Dow Tumbles 250 Points; CarMax Posts Upbeat Results

ACHR

ALGS

ANTE

ATNX

AUTL

BLBD

CRVS

DBVT

DRMA

DRTT

EAST

EFSH

GLDD

GLMD

HCDI

IBRX

IMPL

JAGX

JWAC

LMFA

Larimar Therapeutics, Inc. - Common Stock

LRMR

MGOL

MIND

MNDY

NGMS

NSPR

OCUP

OSUR

PRSO

SANA

SBFM

SWIM

THCH

TIVC

TTCF

TWST

VERO

WISA

WLDS

XBIO

XELA

ZAPP

ZKIN

Gainers


	NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash.


Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Biotech

Health Care

General

Oramed Pharmaceuticals Inc (NASDAQ: ORMP) shares are trading higher after its partner completed Phase 3 trials of oral insulin in type 2 diabetes in China 

Why Oramed Pharmaceuticals Shares Are Trading Higher Today

BBAI

KERN

KLXE

KNOP

LOGI

XPON

U.S. stocks traded higher toward the end of trading, following the release of inflation data.

Gold Tops $1,900 After US CPI Report, S&amp;P 500 Rises 0.5%

ADCT

AGBA

Alternative Asset Management Acquisition Corp

APPH

ARBK

ARVL

AVCT

AVYA

BBBY

BIOR

BITF

COMM

DRTS

GREE

HLBZ

HOWL

IGMS

INUV

LGMK

LIAN

LIPO

MARA

Eaton Vance Massachusetts Municipal Income Trust

MNTS

NCTY

OPRA

PRTY

TANH

TCBP

TERN

YTEN

Gainers


	BigBear.ai Holdings, Inc. (NYSE: BBAI) shares jumped 239% to $2.8715 after the company announced it has been awarded a multiple award $900 million Indefinite Delivery/Indefinite Quantity contract by the U.S. Air Force.


Why KNOT Offshore Partners Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

GPOR

NINE

U.S. stocks turned higher midway through trading, following the release of inflation data.

US Stocks Turn Higher; Dow Jumps 200 Points

INSW

USDP

U.S. stocks traded lower this morning, following the release of inflation data.

Dow Drops 150 Points; US Inflation Rate Slows In December

ACER

HEPA

NCNA

VGFC

WINT

Gainers


	Akerna Corp. (NASDAQ: KERN) rose 97.4% to $1.91 in pre-market trading after the company reported the sale of 365 Cannabis for $2.8 million.


Why Akerna Shares Are Trading Higher By 97%; Here Are 20 Stocks Moving Premarket

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals Inc

Earnings week ahead: Disney, Palantir, Shopify, Uber, Plug Power and more

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Oramed Pharmaceuticals</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/ormp-stock-quote/"><strong>ORMP</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Oramed Pharmaceuticals reported earnings per share of 4 cents. This was above the analyst estimate for EPS of 2 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/ormp-stock-earnings-oramed-pharmaceuticals-for-q1-of-2024/">ORMP Stock Earnings: Oramed Pharmaceuticals Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

ORMP Stock Earnings: Oramed Pharmaceuticals Beats EPS for Q1 2024

Oramed Pharmaceuticals (ORMP) has provided an announcement. David Silberman has stepped down from his roles as CFO, Treasurer, and Secretary at Ora...

Oramed Pharmaceuticals Seeks New CFO After Resignation

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Oramed Pharm (ORMP – Research Report). The company's sha...

H.C. Wainwright Sticks to Their Hold Rating for Oramed Pharm (ORMP)

Oramed Pharm (ORMP) just unveiled an update. Oramed Pharmaceuticals Inc. has announced the appointment of Mr. Avraham Gabay as the new Chief Financ...

Oramed Pharm Names Avraham Gabay as New CFO

Oramed Pharmaceuticals authorizes share buyback program

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>When discussing micro-cap stocks, it&rsquo;s important to recognize their general overlap with the world of <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks.</a> These stocks trade as shares of companies with market capitalizations between $50 million and $300 million. While those numbers may sound worthy to the individual investor, they represent a generally risky position for a handful of reasons.</p>



<p>The first is that micro-cap stocks are often derived from young and relatively unproven companies. Just because a company publicly trades on the <strong>Nasdaq </strong>does not make it a safe investment. The second is that these micro-cap stocks tend to experience less frequent trading than more major companies. This low liquidity can make it harder to sell out of a position should it no longer be lucrative.</p>



<p>Bearing these risks in mind, savvy investors know the value of getting in early on a profitable company. That&rsquo;s because all investing is a function of growth multiplied by time &mdash; the more time, the more potential for growth for your portfolio. Thus, here are three solid micro-cap stocks to consider if you&rsquo;re comfortable with the risk.</p>



<h2>Amplify Energy (AMPY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/03/oilandgasstocks1600-300x169.png" alt="Panorama of Oil and Gas central processing platform in twilight, offshore hard work occupation twenty four working hours. Best oil stocks to buy. Oil &amp; Gas Stocks to Avoid"><div>Source: Oil and Gas Photographer / Shutterstock.com</div></div><p>Small oil and natural gas companies might not be the first thing to come to mind when considering micro-cap stocks, but <strong>Amplify Energy </strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/ampy-stock-quote/"><strong>AMPY</strong></a></span>) is worth putting on your radar. The company is an independent developer focused on acquiring and exploiting oil and natural gas properties exclusively within the United States.</p>



<p>Geographically, the company focuses on <a href="https://www.amplifyenergy.com/operations/default.aspx">low-cost regions</a> for development like Oklahoma, East Texas and North Louisiana, with more expensive basins like the federal waters off the coast of Southern California and the Rocky Mountain West. Year-to-date, the company is up over 12% in value as part of its generally promising financial performance.</p>



<p>Though the company experienced a loss of <a href="https://www.google.com/finance/quote/AMPY:NYSE?sa=X&amp;ved=2ahUKEwj5o5D_tpeHAxVphP0HHWu5BnwQ3ecFegQINxAf">$9.4 million</a> for the first quarter of 2024, it succeeded in surpassing earnings-per-share forecasts by 0.85%, lending hope that its expansion expenses would not hamper its long-term growth. Thus, investors might want to get in early on this geographically diverse and well-managed company.</p>



<h2>Spero Therapeutics (SPRO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/08/doctor_medicine_dna_1600-300x169.jpg" alt="Various graphical representations of medical imagery are shown in front of a doctor using a tablet computer. DNA stock"><div>Source: Shutterstock / PopTika</div></div><p>Perhaps one of the biggest challenges facing modern medicine today is drug-resistant bacteria. This is especially true when considering that just in the U.S. alone more than 2.8 million antimicrobial-resistant infections occur annually, resulting in <a href="https://www.cdc.gov/antimicrobial-resistance/data-research/threats/index.html">35,000 deaths.</a> To address this problem and take advantage of a new sector of antibiotic treatments, <strong>Spero Therapeutics </strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/spro-stock-quote/"><strong>SPRO</strong></a></span>) has gone all-in on developing medicines for multidrug-resistant infections.</p>



<p>Currently, the company is developing several drugs at varying points in the development pipeline, but its most promising candidate seems to be <a href="https://www.sperotherapeutics.com/patients/spr-206">SPR206</a> under the brand name. This drug has reached Phase 2 clinical trials and has shown effectiveness against bacterial pneumonia acquired from hospital ventilator treatments.</p>



<p>While SPRO certainly isn&rsquo;t the only company focused on developing treatments for multidrug-resistant bacteria, its status among micro-cap stocks gives it significant potential to spike following a Food and Drug Administration regulatory approval.</p>



<h2>Oramed Pharmaceuticals (ORMP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/pharmaceuticals_tnxp_1600-300x169.png" alt="medicine research, pharmaceutical background, LJPC stock"><div>Source: Sisacorn / Shutterstock.com</div></div><p>Another fledgling biotech company, <strong>Oramed Pharmaceuticals</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/ormp-stock-quote/"><strong>ORMP</strong></a></span>) aims to address drug accessibility with its product pipeline. One of the factors that can significantly complicate or increase the cost of a treatment is its delivery route. As such, treatments that require injections to successfully enter the body tend to be more expensive due to the cost of syringes, professional injection services and the overall supply chain involved with jabs.</p>



<p>Oramed aims to do away with this, particularly in the <a href="https://oramed.com/pipeline/">insulin delivery sector,</a> by developing oral capsules that bypass stomach absorption and enter the intestine for direct uptake into the bloodstream. In the case of insulin, this would make treating diabetes as simple as taking a pill rather than relying on expensive pumps or complicated needles.</p>



<p>This route of treatment would also expand insulin coverage to developing countries where infrastructure does not allow for easy storage and accessibility to syringes while also nullifying <a href="https://wchh.onlinelibrary.wiley.com/doi/full/10.1002/pdi.2090">infection risks</a> as a result of unsanitary injection practices.</p>



<p><em>On the date of publication, Viktor Zarev did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com </em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines.</em></a></p>



<p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div><p>Viktor Zarev is a scientist, researcher, and writer specializing in explaining the complex world of technology stocks through dedication to accuracy and understanding.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/07/3-micro-cap-moonshots-for-fearless-investors/">3 Micro-Cap Moonshots for Fearless Investors</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 Micro-Cap Moonshots for Fearless Investors

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Oramed Pharmaceuticals</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/ormp-stock-quote/"><strong>ORMP</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Oramed Pharmaceuticals reported earnings per share of 22 cents. This was above the analyst estimate for EPS of 1 cent.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/ormp-stock-earnings-oramed-pharmaceuticals-for-q2-of-2024/">ORMP Stock Earnings: Oramed Pharmaceuticals Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

ORMP Stock Earnings: Oramed Pharmaceuticals Beats EPS for Q2 2024

H.C. Wainwright analyst Ram Selvaraju reiterated a Hold rating on Oramed Pharm (ORMP – Research Report) today. The company's shares closed last Fri...

Oramed Pharm (ORMP) Receives a Hold from H.C. Wainwright

The latest announcement is out from Oramed Pharm ( ($ORMP) ). Oramed Pharmaceuticals Inc. has restructured its financial relationship with Scilex H...

Government Trades

Oramed Pharmaceuticals Inc

top performing ORMP trades

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga